CD4+, IL17 and Foxp3 Expression in Different pTNM Stages of Operable Non-small Cell Lung Cancer and Effects on Disease Prognosis
CD4+, IL17 and Foxp3 Expression in Different pTNM Stages of Operable Non-small Cell Lung Cancer and Effects on Disease Prognosis
复制标题
可手术非小细胞肺癌不同pTNM分期CD4、IL17和Foxp3的表达及其对疾病预后的影响
DOI：
10.7314/apjcp.2012.13.8.3955
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Ma, Xiao-Mei
中科院分区：
文献类型：
--
作者：
Zhang, Guo-Qing;Han, Feng;Ma, Xiao-Mei
目的：探讨CD4(+)、IL17、Foxp3表达对不同pTNM分期可手术非小细胞肺癌(NSCLC)预后的影响。方法：采用免疫组化方法检测102例NSCLC组织及癌旁组织中CD4(+)、IL17、Foxp3的表达，并分析不同pTNM分期与预后的关系。计数资料的比较采用卡方检验。采用Kaplan-Meier单因素分析评估生存差异，并采用COX回归模型分析影响因素与疾病预后的关系。显着性水平为 alpha = 0.05。结果：CD4、IL-17和Foxp3的表达在不同pTNM分期的NSCLC组织中存在显着差异（P < 0.05）。 CD4 表达也是如此（P < 0.05）。 CD4表达阳性组的中位生存时间（MST）明显高于阴性组（25.8/23.9个月）。与stage.相比，stages的MST差异。和。 CD4表达阳性组差异有统计学意义(P<0.05)。 IL-17和Foxp3表达阳性组的MST明显低于相应阴性组（P < 0.05）（分别为25.6/35.1个月和24/35.3个月）。 IL-17阳性表达组的三个阶段中任意两个阶段的MST均有显着性差异（P < 0.05），与Foxp3表达阳性组相同。 TNM分期、CD4阴性表达、IL-17和Foxp3阳性表达是NSCLC预后的主要危险因素。结论：结合临床分期和IL17、Foxp3表达情况可以更好地评估NSCLC的手术预后。
Objective: To investigate the effects of CD4(+), IL17 and Foxp3 expression on prognosis of operable non-small cell lung cancer (NSCLC) with different pTNM stages. Methods: Expression of CD4(+), IL17 and Foxp3 in 102 cases of NSCLC tissues and adjacent cancer tissues was detected by immunohistochemistry and associations with prognosis with different pTNM stages were analyzed. The Chi-square test was used to compare count data. Survival differences were evaluated by Kaplan-Meier single factor analysis and the COX regression model was used to analyze the relationship between influential factors and the disease prognosis. The significance level was alpha = 0.05. Results: Expression of CD4, IL-17 and Foxp3 significantly varied in different pTNM stages of NSCLC tissues (P < 0.05). The same was true for CD4 expression (P < 0.05). The median survival time (MST) in the positive CD4 expression group was evidently higher than that in the negative group (25.8/23.9 months). Compared with stage., the MST difference of stages. and. in the positive CD4 expression group were statistically significant (P < 0.05). The MST in positive IL-17 and Foxp3 expression groups was obviously lower than that in the corresponding negative group (P < 0.05) (25.6/35.1 months and 24/35.3 months, respectively). There was a significant difference of MST between any two of three stages of positive IL-17 expression group (P < 0.05), and it was the same with positive Foxp3 expression group. TNM stage, negative CD4 expression, and positive IL-17 and Foxp3 expression were the main risk factors for the prognosis of NSCLC. Conclusions: Surgical prognosis of NSCLC can be better assessed by the combination of clinical staging and expression of IL17 and Foxp3.